Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s traded shares stood at 3.76 million during the last session, with the company’s beta value hitting 1.13. At the close of trading, the stock’s price was $5.43, to imply a decrease of -1.45% or -$0.08 in intraday trading. The XERS share’s 52-week high remains $5.53, putting it -1.84% down since that peak but still an impressive 68.88% since price per share fell to its 52-week low of $1.69. The company has a valuation of $835.89M, with an average of 4.53 million shares in intraday trading volume over the past 10 days and average of 2.18 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Xeris Biopharma Holdings Inc (XERS), translating to a mean rating of 1.33. Of 3 analyst(s) looking at the stock, 0 analyst(s) give XERS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.04.
Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information
After registering a -1.45% downside in the last session, Xeris Biopharma Holdings Inc (XERS) has traded red over the past five days. The 5-day price performance for the stock is 19.08%, and 36.78% over 30 days. With these gigs, the year-to-date price performance is 60.18%. Short interest in Xeris Biopharma Holdings Inc (NASDAQ:XERS) saw shorts transact 10.63 million shares and set a 5.88 days time to cover.
The extremes give us $4 and $6.6 for target low and target high price respectively. As such, XERS has been trading -21.55% off suggested target high and 26.34% from its likely low.
Xeris Biopharma Holdings Inc (XERS) estimates and forecasts
The rating firms project that company’s revenue will grow 29.17% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 57.61M. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 62.65M.Earnings reports from the last fiscal year show that sales brought in 40.64M and 48.06M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 41.76% before jumping 30.35% in the following quarter.
XERS Dividends
Xeris Biopharma Holdings Inc has its next earnings report out on 2025-Mar-05. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s Major holders
Xeris Biopharma Holdings Inc insiders hold 3.99% of total outstanding shares, with institutional holders owning 42.87% of the shares at 44.65% float percentage. In total, 42.87% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 10.33 million shares (or 7.3531% of shares), all amounting to roughly $23.25 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 7.66 million shares, or about 5.4492% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $17.23 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Xeris Biopharma Holdings Inc (XERS) shares. Going by data provided on Dec 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 4.22 shares. This is just over 2.74% of the total shares, with a market valuation of $22.92 million. Data from the same date shows that the other fund manager holds a little less at 3.77, or 2.45% of the shares, all valued at about 20.47 million.
